Drugs and patents in ATC class J01XX

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
CONTEPO	fosfomycin disodium
FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine
MONUROL	fosfomycin tromethamine
>Tradename	>Generic Name

Last updated: June 10, 2026

J01XX “Other antibacterials” market: How big is it and what products drive revenue?

ATC J01XX is a catch-all bucket for antibacterials not captured by the rest of the ATC J01 series. This classification mixes legacy agents and newer niche products, so market dynamics depend on each country’s reimbursement mix and on whether products are maintained through hospital formulary cycles rather than outpatient scale-up.

What sub-classes sit inside J01XX in practice?

J01XX typically includes:

Novel or niche antibacterials with narrower spectrum or specific route-of-use
Combinations and formulation-defined assets that remain outside common ATC “mainline” categories
Some last-resort or hospital-only therapies where prescribing is protocol-driven

Competitive drivers that shape pricing and volume

Common demand-side factors for J01XX assets:

Hospital stewardship and guideline alignment (restricted prescribing tends to preserve pricing)
Resistance patterns and infection site targeting (favorable uptake when aligned to local antibiograms)
Stewardship-based tendering in EU hospital systems
Short product cycles for line extensions (same active, new formulation or administration device)

IP-driven market share outcomes

In J01XX, patent estates often control “product continuity” rather than large-scale first-wave launches:

Strong compound + formulation + method-of-use coverage can deter Section 505(b)(2) and ANDA entry
ORANGE BOOK visibility is decisive for US generic timing, even when clinical differentiation is modest

What patents protect “Other antibacterials” (J01XX) in the US? How broad are the estates?

A J01XX asset’s enforceable US rights usually come from combinations of:

Active ingredient (compound) patents
Formulation and/or polymorph patents (especially for difficult solubility and stability)
Method-of-use patents (label-relevant indications)
Manufacturing process patents (less determinative unless tied to claimed critical steps)

Typical patent estate structure for J01XX antibacterials

Estate layers

Composition of matter: active, salts, hydrates, solvates, stereoisomers
Formulation: excipient systems, particle size, coatings, lyophilization cycles, reconstitution systems
Method of treatment: patient subsets, infection site, dosing regimens, duration schedules
Manufacturing: control strategies and validated process parameters

How “Other antibacterials” estates differ from larger class categories

J01XX estates often have:

Fewer overlapping competitor compounds, so exclusivity can be concentrated in a single or limited number of families
More patent reliance on formulations or use (because mechanism-of-action differentiation may be narrow)

When does exclusivity for J01XX antibacterials end? What timelines govern generic entry?

Generic entry timing in J01XX in the US is usually driven by the interaction of:

Patent expiration dates (including non-provisional and continuation family timing)
FDA exclusivity (NCE, 505(b)(2) exclusivity, orphan drug exclusivity if applicable)
Trigger events: approval pathway and listed patents in the Orange Book

What determines the “last allowable” date?

For ANDA/505(b)(2) strategy, market entry timing is governed by:

The last expiring listed patent in the Orange Book for the specific NDA/NDA-strength/form
Any exclusivity that is not tied to a patent (exclusivity can block approval even after patent expiry in some scenarios)

Practical “cliff dates” for J01XX

J01XX assets tend to generate predictable entry cliffs when a dominant formulation patent expires later than the active-ingredient patent. In these cases:

The compound patent may expire first
The formulation patent is then used to constrain generic substitution or require design-around

Which J01XX antibacterial patents are most frequently litigated via Paragraph IV?

Paragraph IV (P4) filings happen when a generic applicant challenges at least one Orange Book listed patent as invalid, unenforceable, or not infringed. In J01XX, the highest litigation frequency typically clusters around:

Formulation patents that are difficult to replicate (solubility, stability, reconstitution profiles)
Method-of-use patents tied to specific labeled indications (especially hospital protocols)
Combination and regimen-defined patents

What generic applicants usually challenge

Priority date and obviousness attacks on formulation and manufacturing process claims
Enablement and written description for broad genus claims in older families
Lack of infringement arguments based on differences in excipients, dosage form, or dosing schedule

What is the Orange Book status of “Other antibacterials” in J01XX?

Orange Book status is the gating item for US market-entry planning:

Whether patents are listed for the exact NDC and strength
Whether there are multiple listed patents spanning compound, formulation, and method claims
Whether any patents are subject to a consent decree or settlement-driven entry date

How to interpret “listed patents” in J01XX

For each NDA:

Identify the last-to-expire listed patent for each dosage form
Map each listed patent to claim type:
- Drug substance (composition of matter)
- Drug product (formulation)
- Use (method-of-use)
- Device or administration components (if tied to the drug submission)

How does J01XX’s patent strength compare across key antibacterials?

In J01XX, “strong” estates are less about headline drug substance claims and more about:

Layering and family size (number of continuations and claim scope breadth)
Late-expiring formulation or method patents that remain enforceable after compound expiry
Limited ability for competitors to design around without changing the dosage form or labeled use

Patent estate strength indicators used in practice

Number of active listed patents at the time of generic entry
Whether the last-expiring patents are formulation or use claims
Litigation history: outcomes, sustained injunctions, or settlement-driven launch delays
Whether patents have survived PTAB or reexamination challenges

What formulation patents matter for J01XX antibacterials? (Polymorphs, salts, stability, delivery)

Formulation IP can be the decisive barrier in J01XX due to practical manufacturing constraints and stability requirements.

Common formulation claim targets

Polymorphs, hydrates, and solvates of the active ingredient
Salt selection and crystallization control
Particle size distribution and milling approach
Lyophilized drug cake composition and reconstitution times
Buffer systems that preserve pH stability during infusion
Container closure systems linked to stability evidence

How design-around typically works

Competitors may pursue:

Alternative salts or polymorphs
Modified excipient systems
Different reconstitution volumes or infusion rates
Different manufacturing cycle steps that avoid claimed process conditions

What method-of-use (MOUS) patents constrain prescribing in J01XX?

MOUS patents can restrict generic approvals by:

Making the claimed regimen label-specific
Tying claims to patient populations, infection sites, or duration windows that align with prescribing guidance

MOUS claim patterns seen in hospital antibacterials

Treatment of infections with specific organisms
Use in patients with defined clinical features (severity, immunocompromised status)
Specific dosing schedules and duration to reach exposure targets
Sequential regimens (induction then consolidation)

Why MOUS matters even with off-label realities

Even where off-label use exists, generic approval under US law focuses on the approved labeling. A strong MOUS patent tied to label language can:

Delay approval until infringement risk is removed
Increase settlement leverage for the brand

What patent litigation affects J01XX antibacterials? Injunction and settlement mechanics

J01XX litigation outcomes usually determine:

Whether generics can launch “at risk” before final resolution
Whether brand owners secure exclusivity-like behavior via settlement entry dates

Typical litigation pathways

ANDA Paragraph IV suits in US district courts (often early stage claim construction disputes)
Stay mechanisms pending appeal in some circumstances
Consent judgments that convert legal timing into a fixed launch calendar

What to look for in case records

Which patents are asserted (compound vs formulation vs MOUS)
Claim construction outcomes (narrow vs broad interpretation)
Whether settlements include “carve-outs” for alternative formulations, strengths, or administration routes

What Paragraph IV entry risks exist for J01XX antibacterials?

Key risk factors for generic launch:

Brand estate includes late-expiring formulation or MOUS patents
Claim scope is tight and requires specific product features
Litigation has already narrowed valid claim sets, making subsequent attempts less defensible

What lowers generic entry risk

Early settlement and easy design-around options
Patents that expire soon relative to trial timelines
Clear non-infringement based on dosage form or regimen differences

How do ATC J01XX dynamics compare with adjacent antibacterials categories?

J01XX differs from more structured categories like beta-lactam/betalactamase inhibitor or fluoroquinolones mainly in:

Heterogeneity: “Other antibacterials” mixes agents with different development cycles and resistance-driven demand profiles
Patent strategy: more reliance on formulation and use claims to sustain differentiation under crowded resistance markets

Strategic implication

Companies entering J01XX usually win by:

Securing label-aligned clinical differentiation
Building an estate that delays generic substitution on product continuity, not only on substance

Commercial and regulatory overlays: FDA pathway effects on timing and enforcement

US regulatory timing can shift market outcomes:

505(b)(2) pathways can support earlier label expansions that extend commercial use while patents are active
Orphan drug and NCE exclusivities can extend blocking periods beyond patent expiry in certain scenarios

EU and other markets: why patent enforcement differs

EU market exclusivity and national patent enforcement can:

Create staggered effective exclusivity by country
Affect company’s willingness to accept risk for at-home supply versus centralized distribution

Where do licensing deals and settlements concentrate in J01XX?

Settlements in J01XX usually center on:

Allowing delayed entry in exchange for generic licensing or noninfringement agreements
Cross-licensing of formulation know-how or process improvements
Agreement on specific NDC versions (strength, dosage form, or reconstitution details)

What licensing deals often cover

Technology enabling manufacturing at scale without infringing process patents
Access to reference standards for analytical comparability
Labeling commitments to minimize MOUS infringement risk

J01XX “what to watch next”: the specific triggers that usually precede generic erosion

Across the class, generic acceleration tends to follow:

Expiry of the last listed formulation patent for the dominant NDC
Settlement-driven carve-outs that remove the brand’s injunction leverage
Label changes that narrow the asserted MOUS scope
New competitors obtaining approval via different salts/polymorphs that fall outside infringement claims

Key Takeaways

J01XX is heterogeneous, so market and patent dynamics are asset-specific and often hinge on formulation and method-of-use patents rather than only compound families.
Generic entry timing in the US is controlled by Orange Book-listed patents tied to each strength and dosage form, with exclusivity acting as an additional blocker where applicable.
Paragraph IV litigation in J01XX is most likely to cluster around late-expiring formulation and label-relevant method-of-use claims that are hard to design around.
In commercial terms, brand owners tend to defend product continuity: delayed generic substitution via layered estates and settlement-calendars rather than relying on a single compound expiry date.
Competitive pressure increases sharply after the last-to-expire listed patent for the relevant NDC, particularly where brand continuity depends on a specific formulation or regimen claim.

FAQs

1) How do formulation patents in J01XX change ANDA approval risk?

They can force design-around on excipients, polymorph/salt, particle size, or reconstitution parameters that define the Orange Book-listed NDC, creating high noninfringement and invalidity leverage points in P4 suits.

2) What role do method-of-use (MOUS) patents play if generics seek “skinny label”?

MOUS can block approval if the proposed labeling still covers the patented regimen. When only some indications are carved out, MOUS coverage can still limit approval and delay launch.

3) Which J01XX patent families typically expire last?

Formulation and drug product patents tied to stability and delivery, plus late-continuation claims in the same family designed to push out effective expiration, often represent the last-to-expire assets.

4) How do settlement agreements affect launch calendars in J01XX?

Settlements commonly convert litigation uncertainty into fixed entry dates, sometimes with product-scope carve-outs by strength, dosage form, or labeling to manage infringement risk.

5) Does FDA exclusivity matter in J01XX even after patent expiry?

Yes, where applicable, FDA exclusivity can delay approval independently of patent status, turning “patent expiry” into a necessary but not sufficient condition for generic launch.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. Drug Competition, Charges, and Patents (the Hatch-Waxman Program) overview. U.S. Food and Drug Administration.
FDA. Guidance for Industry: Preparation of Amended Applications/Or Other Changes to NDA/ANDA. U.S. Food and Drug Administration.